Myxothiazol
![]() | |
| Names | |
|---|---|
| IUPAC names
7-{2'-[(1S,2E,4E)-1,6-dimethyl-2,4-heptadienyl] [2,4'-bithiazol]-4-yl}-3,5-dimethoxy-4-methyl- (2E,4R,5S,6E)-2,6-heptadienamide | |
| Identifiers | |
| 76706-55-3 | |
| MeSH | Myxothiazol |
| PubChem | 6437357 |
| Properties | |
| C25H33N3O3S2 | |
| Molar mass | 487.68 g/mol |
| Except where otherwise noted, data are given for materials in their standard state (at 25 °C [77 °F], 100 kPa). | |
| | |
| Infobox references | |
Myxothiazol (produced by the myxobacterium Myxococcus fulvus) is an inhibitor of the mitochondrial cytochrome bc1 complex (coenzyme Q - cytochrome c reductase).
Myxothiazol is a competitive inhibitor of ubiquinol, and binds at the quinol oxidation (Qo) site of the bc1 complex, blocking electron transfer to the Rieske iron-sulfur protein. Binding of myxothiazol induces a red-shift to the visible absorption spectrum of reduced haem bl. In contrast to stigmatellin, myxothiazol does not form a hydrogen bond to the Rieske iron-sulfur protein, binding instead in the 'b-proximal' region of the cytochrome b Qo site. Movement of the cytoplasmic domain of the Rieske protein is therefore unaffected by the binding of this inhibitor.
This article is issued from Wikipedia - version of the Tuesday, July 07, 2015. The text is available under the Creative Commons Attribution/Share Alike but additional terms may apply for the media files.
